[EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
Harefuah
; 159(1): 29-30, 2020 Jan.
Article
em He
| MEDLINE
| ID: mdl-31930804
INTRODUCTION: Bullous pemphigoid is a common autoimmune blistering disorder, characterized by sub-epidermal bullae formation, that tends to affect older patients. We report on a 78 -year-old male patient suffering from bullous pemphigoid, whose disease persisted despite treatment with potent topical corticosteroids, systemic tetracyclines, prednisone and azathioprine. Recently, omalizumab was reported to be effective in several patients with resistant bullous pemphigoid. Omalizumab is a monoclonal antibody against IgE, approved for the treatment of asthma and chronic urticaria and known for its excellent safety profile. The patient was treated accordingly with omalizumab for his bullous pemphigoid with dramatic and rapid regression of his disease.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Penfigoide Bolhoso
/
Antialérgicos
/
Omalizumab
Limite:
Aged
/
Humans
/
Male
Idioma:
He
Revista:
Harefuah
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Israel
País de publicação:
Israel